ORIC Pharmaceuticals Ownership | Who Owns ORIC Pharmaceuticals?
ORIC Pharmaceuticals Ownership Summary
ORIC Pharmaceuticals is owned by 15.63% institutional investors, 9.56% insiders, and 74.81% retail investors. Pfizer is the largest institutional shareholder, holding 7.62% of ORIC shares. ACAP Strategic A is the top mutual fund, with 2.70% of its assets in ORIC Pharmaceuticals shares.
ORIC Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | ORIC Pharmaceuticals | 15.63% | 9.56% | 74.81% |
| Sector | Healthcare Stocks | 279.19% | 10.62% | -189.81% |
| Industry | Biotech Stocks | 63.96% | 10.74% | 25.30% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Pfizer | 5.38M | 7.62% | $43.39M |
| Nextech invest | 5.29M | 7.49% | $42.66M |
| Blackrock funding, inc. /de | 5.11M | 7.25% | $41.26M |
| Blackrock | 4.83M | 7.17% | $34.15M |
| Viking global investors lp | 4.43M | 6.28% | $35.76M |
| Alkeon capital management | 3.90M | 5.53% | $31.51M |
| Column group | 3.54M | 5.02% | $28.57M |
| Ecor1 capital | 3.42M | 4.85% | $27.58M |
| Vanguard group | 3.20M | 4.54% | $25.85M |
| Vr adviser | 3.18M | 4.48% | $17.76M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Column group | 3.54M | 51.26% | $28.57M |
| Superstring capital management lp | 1.58M | 11.05% | $12.76M |
| Invus financial advisors | 1.01M | 7.98% | $7.12M |
| Nextech invest | 5.29M | 6.92% | $42.66M |
| First turn management | 2.03M | 2.28% | $11.31M |
| Silverarc capital management | 1.18M | 2.08% | $9.51M |
| Pfizer | 5.38M | 1.67% | $43.39M |
| Vr adviser | 3.18M | 1.51% | $17.76M |
| Bioimpact capital | 1.40M | 1.34% | $7.81M |
| Vivo capital | 1.28M | 1.16% | $10.31M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Pfizer | 5.38M | 1.67% | 5.38M |
| Blackrock | 4.83M | 0.00% | 1.65M |
| Bioimpact capital | 1.40M | 1.34% | 1.40M |
| Schonfeld strategic advisors | 724.32K | 0.03% | 724.32K |
| Orbimed advisors | 700.00K | 0.09% | 700.00K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Frazier life sciences management | 1.41M | 0.36% | -2.48M |
| Fmr | 2.47M | 0.00% | -1.91M |
| Avidity partners management lp | - | - | -1.27M |
| Vr adviser | 3.18M | 1.51% | -1.21M |
| Adage capital partners gp | - | - | -500.00K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Pfizer | 5.38M | 1.67% | 5.38M | $43.39M |
| Bioimpact capital | 1.40M | 1.34% | 1.40M | $7.81M |
| Schonfeld strategic advisors | 724.32K | 0.03% | 724.32K | $5.85M |
| Orbimed advisors | 700.00K | 0.09% | 700.00K | $3.91M |
| Dafna capital management | 242.00K | 0.38% | 242.00K | $1.35M |
Sold Out
| Holder | Change |
|---|---|
| Capital performance advisors llp | -1.00 |
| Nelson, van denburg & campbell wealth management group | -8.00 |
| Ronald blue trust | -64.00 |
| Srs capital advisors | -68.00 |
| Skopos labs | -105.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | 11 | -91.91% | 11,102,130 | -85.35% | 15 | 0.14% | 8 | -89.87% | 2 | -92.86% |
| Dec 31, 2024 | 39 | -68.29% | 10,134,721 | -85.49% | 14 | 0.15% | 26 | -58.06% | 7 | -81.58% |
| Sep 30, 2024 | 123 | 10.81% | 69,828,652 | 3.33% | 98 | 0.98% | 62 | -16.22% | 38 | 100.00% |
| Jun 30, 2024 | 111 | -2.63% | 67,581,249 | 5.85% | 100 | 1.12% | 74 | 10.45% | 19 | -32.14% |
| Mar 31, 2024 | 114 | 20.00% | 63,846,117 | 26.08% | 94 | 1.22% | 67 | 17.54% | 28 | 40.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| ACAP Strategic A | 1.92M | 2.70% | - |
| Vanguard Total Stock Mkt Idx Inv | 1.88M | 2.65% | - |
| Vanguard US Total Market Shares ETF | 1.88M | 2.65% | - |
| iShares Russell 2000 ETF | 1.59M | 2.23% | 777.00 |
| Fidelity Growth Compy Commingled Pl S | 1.31M | 1.84% | - |
| Fidelity Growth Compy Commingled Pl O | 1.28M | 1.81% | - |
| T. Rowe Price Health Sciences | 958.71K | 1.35% | -14.48K |
| SPDR® S&P Biotech ETF | 873.70K | 1.23% | 1.13K |
| Vanguard Institutional Extnd Mkt Idx Tr | 737.89K | 1.04% | 1.75K |
| Fidelity Growth Company Fund | 725.73K | 1.02% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jun 11, 2025 | Piscitelli Dominic | Chief Financial Officer | Sell | $17.02K |
| Jun 10, 2025 | Piscitelli Dominic | Chief Financial Officer | Sell | $3.24K |
| Jun 11, 2025 | Piscitelli Dominic | Chief Financial Officer | Sell | $12.76K |
| Jun 09, 2025 | Piscitelli Dominic | Chief Financial Officer | Sell | $3.00K |
| Jun 06, 2025 | Piscitelli Dominic | Chief Financial Officer | Sell | $26.02K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q2 | - | 5 |
| 2025 Q1 | - | - |
| 2024 Q4 | - | 3 |
| 2024 Q2 | - | - |
| 2024 Q1 | - | 3 |
ORIC Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools